Selected Announcements|Zhonghai Real Estate's sales during the year exceeded 287 billion yuan, up 11.8% from the previous year; Sunac China's forced convertible bonds were converted to 1.9 billion US dollars for the first time

Futu News ·  12/07/2023 08:04

Big announcement

1. China's overseas development: From January to November, contract sales reached a total of 287.028 billion yuan, up 11.8% year on year

$CHINA OVERSEAS (00688.HK)$An announcement was issued. In November 2023, contract property sales for a series of Chinese overseas companies were about RMB 22,945 billion, a year-on-year decrease of 4.8%; while the corresponding sales floor area was about 967,900 square meters, a year-on-year decrease of 20.3%. From January to November 2023, the cumulative contract property sales amount of Chinese overseas companies was about RMB 287.028 billion, and the corresponding cumulative sales floor area was about 12,373,400 square meters, up 11.8% and 4.0% year-on-year respectively.

2. Sunac China's forced conversion bonds were converted to US$1.9 billion for the first time

$SUNAC (01918.HK)$It was announced that during the first conversion period of mandatory convertible bonds, conversion notices with a total principal amount of about US$1,904 million have been received, accounting for about 69.23% of the initial issuance amount. At a conversion price of 6 yuan per share, the company has issued a total of 2,475 billion shares to converted holders.

3. China Electric Power: The consolidated total electricity sales volume for the first 10 months was 8289.1 million megawatt-hours, a year-on-year decrease of 7.36%

$CHINA POWER (02380.HK)$It was announced that for the ten months ending October, the consolidated total electricity sales volume was 82.89 million megawatt-hours, a year-on-year decrease of 7.36%. Among them, hydroelectric power generation was 10.33 million megawatt-hours, a decrease of 40.02%; wind power generation was 13.65 million megawatt-hours, an increase of 67.05%; and photovoltaic power generation was 11.2 million megawatt-hours, an increase of 35.21%.

4. CRRC: Signed contracts totaling about 28.99 billion yuan in October-December

$CRRC (01766.HK)$It was announced that a number of contracts were signed between October and December, with a total amount of RMB 28.99 billion, accounting for 13% of the company's 2022 operating income under Chinese accounting standards.

5. Shanghai Pharmaceutical: WST04 preparation obtained a clinical trial approval notice

$SH PHARMA (02607.HK)$An announcement was issued. Recently, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd. (“Shangyao Xinyi”), a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration for the WST04 preparation (capsule) (hereinafter referred to as “WST04 preparation” or “this project”), which will begin domestic phase I clinical trials in the near future. According to reports, the WST04 preparation is an oral microbiologically active bacterial preparation intended for the treatment of advanced malignant solid tumors. Preclinical studies have shown that WST04 preparations can significantly enhance the antitumor effects of immune checkpoint inhibitors.

Earnings Report

$YIXIN (02858.HK)$The total amount of automobile financing in the third quarter reached 17.7 billion yuan, and the amount of new energy vehicle financing increased 219.4% year-on-year

Investment and operation

$CRRC (01766.HK)$A total of about 28.99 billion yuan of contracts was signed in October-December

$CHINA POWER (02380.HK)$: The consolidated total electricity sales volume for the first 10 months was 82,891 million megawatt-hours, a year-on-year decrease of 7.36%

$CANSINOBIO (06185.HK)$: Initiation of phase I clinical trials of the Tdcp vaccine for adolescents and adults and completion of enrollment of the first case of subjects

$SH PHARMA (02607.HK)$: WST04 preparation obtained a notice of approval for clinical trials

$ANTENGENE-B (06996.HK)$: The Macao Drug Administration approves the marketing application for ATG-010 (celinisol) as a new drug for the treatment of recurrent and/or refractory multiple myeloma

$KINGKEY FIN INT (01468.HK)$Plans to sell 49% of Jingji Premium Wealth Management's shares for HK$1.66 million

Housing enterprise data

$CHINA OVERSEAS (00688.HK)$: From January to November, cumulative contract sales of 287.028 billion yuan were achieved, up 11.8% year on year

$SUNAC (01918.HK)$: From January to November, a cumulative contract sales amount of 79.28 billion yuan was achieved, a year-on-year decrease of 50.8%

$POLY PROPERTY (00119.HK)$From January to November, the cumulative contract sales amount was about 50.6 billion yuan, up 12% year on year

$CH OVS G OCEANS (00081.HK)$: From January to November, cumulative contract sales of 40.309 billion yuan increased 11.7% year-on-year

$GEMDALE PPT (00535.HK)$: The cumulative contract sales volume from January to November was 32.662 billion yuan, a year-on-year decrease of 39.26%

$COUNTRY GARDEN (02007.HK)$: In November, equity contract sales reached 6.11 billion yuan

$KWG GROUP (01813.HK)$: The pre-sale amount in November was 1,251 billion yuan

Resumption of trading and suspension

$COFCO PACKAGING (00906.HK)$Privatized with a premium of about 6.0% and resumed trading on December 7

Equity incentives

$SINO BIOPHARM (01177.HK)$: The trustee buys 2 million shares under the restricted share award scheme

Repurchase cancellation

$TENCENT (00700.HK)$Repurchase of 1.3 million shares at a cost of HK$403 million on December 6

$HSBC HOLDINGS (00005.HK)$On December 5, 2,721,200 shares were repurchased at a cost of HK$162 million

$AIA (01299.HK)$Repurchase of 2.143 million shares at a cost of HK$135 million on December 6

$BEKE-W (02423.HK)$On December 5, it spent 10 million US dollars to repurchase 1,974 million shares

$XIAOMI-W (01810.HK)$Repurchase of 3.2 million shares at a cost of HK$47.63 million on December 6

$BOSS ZHIPIN-W (02076.HK)$On December 5, 550,000 shares were repurchased at a cost of 3.9947 million US dollars

$CONCH CEMENT (00914.HK)$On December 6, it spent 18.455,800 yuan to repurchase 826,900 A-shares

$COSCO SHIP HOLD (01919.HK)$On December 6, it spent HK$16.935 million to repurchase 2,393,500 shares

$YUM CHINA (09987.HK)$On December 5, 49,000 shares were repurchased at a cost of 2 million US dollars

$ESR (01821.HK)$On December 6, 1.5 million shares were repurchased at a cost of HK$14.81 million

$CONCORD NE (00182.HK)$On December 6, 17.33 million shares were repurchased at a cost of HK$11.25 million


The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment